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Objectives We conducted a prospective randomized trial to compare the clinical impact of conventional risk factor modifi-
cation to that associated with the addition of coronary artery calcium (CAC) scanning.
Background Although CAC scanning predicts cardiac events, its impact on subsequent medical management and coronary
artery disease risk is not known.
Methods We assigned 2,137 volunteers to groups that either did undergo CAC scanning or did not undergo CAC scanning be-
fore risk factor counseling. The primary end point was 4-year change in coronary artery disease risk factors and Fra-
mingham Risk Score. We also compared the groups for differences in downstream medical resource utilization.
Results Compared with the no-scan group, the scan group showed a net favorable change in systolic blood pressure
(p  0.02), low-density lipoprotein cholesterol (p  0.04), and waist circumference for those with increased abdomi-
nal girth (p  0.01), and tendency to weight loss among overweight subjects (p  0.07). While there was a mean rise
in Framingham Risk Score (FRS) in the no-scan group, FRS remained static in the scan group (0.7  5.1 vs. 0.002 
4.9, p  0.003). Within the scan group, increasing baseline CAC score was associated with a dose-response improve-
ment in systolic and diastolic blood pressure (p  0.001), total cholesterol (p  0.001), low-density lipoprotein choles-
terol (p  0.001), triglycerides (p  0.001), weight (p  0.001), and Framingham Risk Score (p  0.003). Down-
stream medical testing and costs in the scan group were comparable to those of the no-scan group, balanced by
lower and higher resource utilization for subjects with normal CAC scans and CAC scores 400, respectively.
Conclusions Compared with no scanning, randomization to CAC scanning was associated with superior coronary artery dis-
ease risk factor control without increasing downstream medical testing. Further study of CAC scanning, including
pre-specified treatment recommendations, to assess its impact of cardiovascular outcomes is warranted. (Early
Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research [EISNER]; NCT00927693)
(J Am Coll Cardiol 2011;57:1622–32) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.019Coronary artery calcium (CAC) scanning can predict ad-
verse clinical events (1–4), but its direct impact on future
coronary artery disease (CAD) risk and downstream medi-
cal costs, relative to that of conventional medical practice,
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April 12, 2011:1622–32 Randomization to Coronary Calcium Scan Versus No Scanhypothesis that performing CAC scanning of asymptomatic
volunteers would lead to a beneficial sustained 4-year effect
on their CAD risk factors. Secondarily, we assessed the
impact of CAC scanning on downstream medical resource
utilization and healthcare costs.
Methods
The trial participants consisted of 2,137 subjects who were
recruited between May 2001 and May 2005 at Cedars-Sinai
Medical Center (CSMC) (Fig. 1). We preferentially selected
middle-aged individuals with CAD risk factors and ex-
cluded subjects with a history of cardiac or cerebrovascular
disease or chest pain, age 80 years, pregnancy, significant
edical comorbidity, and prior coronary catheterization or
rior CAC scanning. After recruitment, subjects were ran-
omized into a group that was either scheduled for CAC
canning (scan group) or not scheduled for calcium scanning
no-scan group). To encourage subjects’ enrollment into our
tudy, the ratio of randomization was 2:1 for receiving a CAC
can. This research was approved by the CSMC institutional
eview board, and all subjects signed informed consent.
aseline clinical assessment. Baseline measurements were
btained for the following: fasting total cholesterol, high-
ensity lipoprotein (HDL), low-density lipoprotein (LDL)
holesterol, triglycerides, and fasting serum glucose; systolic
nd diastolic blood pressure measurements; height; weight;
nd waist circumference. Physical activity was assessed
ichotomously (yes/no) according to subjects’ response to
he following question: “Do you exercise regularly (3 to 4
imes a week) for at least 30 minutes each time?” Ten-year
isk of CAD was calculated by the Framingham Risk Score
FRS) in accordance with published guidelines (5,6). Sub-
ects with diabetes mellitus were automatically assigned a
igh risk FRS of 20%, or higher if so calculated (6).
isk factor counseling. At the baseline examination, one
f our nurse practitioners, each having been trained regard-
ng the need for impartiality and consistency in counseling,
onducted a private risk factor counseling session. To
urther standardize counseling, the nurse practitioner
rinted a customized risk factor management packet for
ach subject containing the American Heart Association
uidelines on cardiac risk factors (7), subjects’ results for
ach risk factor, and information on how to improve their
isk profiles. The nurse practitioner reviewed the packet
ith each subject first, and then additionally also reviewed
he CAC images, and CAC score and percentile score with
ubjects in the scan group. Subjects were instructed that the
resence of any calcium constituted evidence of atheroscle-
osis. To preserve subject anonymity as required by our
nstitutional review board, test results were not sent directly
o subjects’ physicians, but subjects were given 2 copies of
heir anonymized CAC scan report and were encouraged to
hare their results with their physician.
oronary calcium scanning. Scanning was performed us-
ng electron beam (GE-Imatron Inc., San Francisco, Cali-ornia) or multislice computed
omography (Siemens Medical
ystems, Forchheim, Germany).
he imaging protocol involved
cquiring a single scan of 30 to
0 slices of 3 or 2.5 mm thick-
ess (8). Foci of CAC were iden-
ified by an experienced radio-
raphic technologist and scored
sing semiautomatic commercial
oftware on a NetraMD work-
tation. Total calcium score was
etermined by summing lesion-
pecific scores, calculated as the
roduct of the area of each calci-
ed focus and peak CT number
erived according to the Agat-
ton method (9). Estimated radi-
tion dose ranged from 1 to 2 mSv.
-year clinic visit. Trial participants were asked to return for
a follow-up clinic visit at 4 years, during which all assessments
obtained at baseline were repeated and CAC scanning was
performed in all subjects. Of the 2,137 enrolled subjects, 713
(33.4%) were randomized to the no-scan group and 1,424
(66.6%) to the scan group (Fig. 1). Of these, 584 (81.9%)
no-scan and 1,256 (88.2%) scan subjects completed the
follow-up clinic evaluation and questionnaire (p  0.001).
There were 35 (4.9%) no-scan subjects and 38 (2.7%) scan
subjects who could not return for the follow-up clinic evalua-
tion and completed the questionnaire only; these subjects were
not assessed for clinic-determined risk factors at 4 years.
Within the no-scan group, 52 (7.3%) were lost to follow-up,
17 (2.4%) withdrew from the trial, and 4 (0.6%) died before
4-year follow-up. Within the scan group, 61 (4.3%) were lost
to follow-up, 13 (0.9%) withdrew, and 17 (1.2%) died before
follow-up. There were 21 (2.9%) no-scan subjects and 39
(2.7%) scan subjects who indicated they met eligibility criteria
at enrollment but later disclosed an exclusion criterion that
resulted in their subsequent exclusion. Three no-scan subjects
and 8 scan subjects did not undergo repeat CAC scanning at
the time of their 4-year clinic visit.
Primary outcomes. The primary outcome of our trial was
change in CAD risk profiles at 4 years among the scan
subjects versus no-scan subjects, including change in global
risk as assessed by the FRS.
Secondary outcomes. Secondary outcomes included com-
parison of the randomized groups relative to rates of
downstream tests and procedures, health care costs, and
occurrence of adverse clinical events. To assess costs, we
applied nationwide, average Medicare diagnosis-related
group reimbursement rates using the PC Pricer prospective
payment system estimator. Outpatient service costs were de-
rived by use of the outpatient prospective payment amounts
(nationwide and specific locality) based on healthcare common
procedure codes. The Medicare planner for retail and mail-
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CI  confidence interval
CSMC  Cedars-Sinai
Medical Center
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Randomization to Coronary Calcium Scan Versus No Scan April 12, 2011:1622–32trial (10). Costs were inflation-adjusted and discounted at a
rate of 3% per year. A $150 charge was assigned for CAC
scanning (although it was performed at no charge). Clinical
events included cardiac and all-cause death and nonfatal
myocardial infarction. Cause of death status was confirmed by
medical record review. Diagnosis of myocardial infarction was
confirmed by enzymatic elevation and electrocardiographic
changes consistent with acute infarction.
Statistical analyses. Changes in risk factors were mainly
expressed as the clinical value at 4 years minus the value at
baseline, with negative change indicating a reduction in risk
factor. All data were analyzed using STATA version 11
(StataCorp, College Station, Texas). Continuous variables
were expressed as mean  SD or median (25th, 75th percen-
tiles) and compared using 2-sample t tests for approximately
normal variables or Wilcoxon rank-sum test for non-normal
Figure 1 Summary of Trial Design and Subject Disposition at 4
CAC  coronary artery calcium.variables. Likewise, continuous variables in 2 groups were ucompared using 1-way analysis of variance or Kruskal-Wallis
test for non-normal variables, and if ordered, were also tested
using Cuzick’s test for trend. Categorical variables were com-
pared using Pearson’s chi-square test or Fisher exact test where
there were cell counts of 6. Ordered categorical variables
were further assessed using the chi-square test for trend.
Annual event rates were calculated as the % number of events
divided by person-years. Progression of CAC scores in the scan
group were assessed by comparing the CAC score at 4 years to
that at baseline. Relative change in CAC scores were assessed
according to the formula developed by the MESA (Multi-
Ethnic Study of Atherosclerosis) study: ln(CACy425) 
n(CACbl25). We identified progression of CAC to have
ccurred if subjects converted from a negative to a positive scan
r if subjects were 75th percentile for progression by the
ESA formula. All clinically relevant predictors were tested
























1625JACC Vol. 57, No. 15, 2011 Rozanski et al.
April 12, 2011:1622–32 Randomization to Coronary Calcium Scan Versus No Scanalone and in conjunction with age, sex, and length of
follow-up time. Furthermore, both forward and backward
stepwise logistic regression were used to find the best
predictors of progression, where candidate variables with
a p value 0.05 were entered and those with a p value
0.10 were removed from the model. Separate models
were made for baseline and treatment variables before
combining into a single overall model. Models were
evaluated for goodness of fit and other parameters (results
not shown). A p value 0.05 was considered significant.
Results
Subject characteristics. The clinical characteristics of the 2
andomized groups are shown in Table 1. The 2 groups
ere comparably matched in terms of age, sex, socioeco-
omic factors, cardiac risk factors, medication use, and FRS.
omparison of CAD risk factors at 4 years in the
andomized groups. Table 2 shows the change in CAD
isk factor status in the randomized groups at 4-year
ollow-up. Compared with the no-scan group, the scan
roup had significantly greater reduction in systolic blood
ressure and serum LDL cholesterol levels, reduction in
aist circumference for those with increased abdominal
irth at baseline, and modest tendency towards less weight
ain among subjects who were overweight (body mass index
25 kg/m2). There was no significant difference between
the 2 groups with respect to HDL cholesterol, triglyceride, and
glucose levels; smoking cessation; and new exercise activity.
Notably, the 4-year mean FRS score increased in the no-scan
group compared with baseline FRS (0.7  5.1), but remained
essentially unchanged in the scan group (0.002  4.9, p 
0.003) even though they were 4 years older.
Comparison of medical resource utilization in the ran-
domized groups. More scan than no-scan subjects had
initiation of new antihypertensive medication use, and there
was a modest tendency toward greater use of lipid-lowering
medications. Within both groups, continuation of lipid
lowering and antihypertensive medication remained high at
4 years for those on these medications at baseline. As shown
in Table 2, the 2 randomized groups did not differ in 4-year
utilization of stress tests, carotid ultrasound studies, noninva-
sive and invasive coronary angiogram studies, and revascular-
ization procedures. The overall medical procedure costs were
comparable in both randomized groups, although medication
costs tended to be higher in the scan group.
Comparison of clinical events in the randomized groups.
Within our study population, there were 3 cardiac deaths
(annualized cardiac mortality rate of 0.04%) and 21 all-cause
deaths (annualized all-cause mortality rate of 0.3%). One
cardiac death (0.2%) and 4 all-cause deaths (0.6%) occurred in
the no-scan group, and 2 cardiac deaths (0.2%) and 17
all-cause deaths (1.3%) occurred in the scan group (p  1.00
for cardiac and p  0.24 for all-cause mortality). Myocardial
infarction occurred in 2 (0.3%) no-scan subjects and 10 (0.8%)
scan subjects (p  0.36). The combined number of deaths (and/or myocardial infarction were 6 (1.0%) in the no-scan
group and 27 (2.1%) in the scan group (p  0.08).
Impact of baseline CAC score on 4-year CAD risk
profiles. Within the scan group, increasing baseline CAC
score was associated with a proportionally greater improve-
ment in most CAD risk factors at follow-up (Table 3). An
inverse dose-response relationship was observed between
increasing baseline CAC scores and systolic and diastolic
blood pressure, serum cholesterol, LDL cholesterol, and
triglycerides. In addition, greater weight loss was noted
among overweight subjects with CAC scores 100 at
baseline, and for subjects with increased abdominal girth,
the greater decline occurred among those with CAC scores
400 at baseline. There was also a trend toward more
exercise with increasing CAC scores. The FRS rose in
subjects with a zero CAC score, but decreased in subjects
with evidence of CAC at baseline.
Impact of baseline CAC score on medical resource
utilization. A progressive increase in new cardiac medica-
tions occurred with increasing baseline CAC scores, partic-
ularly for lipid-lowering medications. Among subjects on
medications at baseline, adherence rates at 4 years were high
for use of lipid-lowering and antihypertensive medications.
The frequency of both noninvasive and invasive procedures
as well as procedural costs also increased with increasing
baseline CAC scores, but the rate of catheterization and
revascularization was low in all groups. Procedural costs
were low for subjects with no CAC and much higher for
subjects with CAC scores 400.
Comparison of the no-scan group to subjects with a
normal baseline CAC scan. Comparison of the no-scan
randomized group to the scan subgroup with normal CAC
scans (CAC score  0) is shown in Table 4. There was no
ifference between these groups in 4-year CAD risk pro-
les, although the normal scan subjects had lower rates of
nitiation of new lipid medication. Similarly, adherence to
aseline medications did not differ between these groups.
ower downstream rates of noninvasive tests and invasive
rocedure utilization were noted for subjects with normal
AC scans. Overall, incurred costs were lower in the
ormal scan subjects compared with the no-scan subjects,
ncluding 37% lower procedures costs (p  0.001) and 26%
lower medication costs (p  0.005).
Assessment of CAC scores at 4 years. The CAC score at
4 years was mean 147  335, or median 11 (0, 124) in the
no-scan group and mean 163  431 or median 12 (0, 124)
in the scan group (p  0.89). The distribution of CAC
scores was similar between the no-scan and scan groups at 4
years: 43% and 42% had a zero CAC score, 29% and 31%
had a CAC score of 1 to 99, 18% and 17% had CAC scores
of 100 to 399, and 11% in both groups had CAC scores
400 (p  0.75 for all subgroups). Overall, 385 (31%) of
the 1,248 scan subjects showed conversion from a normal to
abnormal CAC scan (n  73) or change in CAC score that
as 75th percentile for progression by the MESA formula
n  273) or both (n  39). In the baseline predictors model
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Randomization to Coronary Calcium Scan Versus No Scan April 12, 2011:1622–32Baseline CharacteristicsTable 1 Baseline Characteristics
Parameters Overall (n  1,934) No-Scan Group (n  623) Scan Group (n  1,311) p Value
Age, yrs 58.5 8.4 58.4 8.2 58.6 8.5 0.75
Male 1,015 (52.5%) 327 (52.5%) 688 (52.5%) 1.00
Race/ethnicity
Caucasian 1,487 (77.0%) 493 (79.1%) 994 (76.0%)
African-American 97 (5.0%) 26 (4.2%) 71 (5.4%)
Asian/Pacific Islander 202 (10.5%) 62 (10.0%) 140 (10.7%)
Hispanic/Latino 81 (4.2%) 23 (3.7%) 58 (4.4%)
Other 64 (3.3%) 19 (3.0%) 45 (3.4%) 0.59
Level of education
High school 13 (0.7%) 3 (0.5%) 10 (0.8%)
High school/tech 156 (8.3%) 43 (7.1%) 113 (8.9%)
Some college 412 (21.9%) 137 (22.5%) 275 (21.6%)
College 533 (28.3%) 197 (32.3%) 336 (26.4%)
Graduate education 767 (40.8%) 230 (37.7%) 537 (42.3%) 0.87*
Annual income
$20,000 75 (4.2%) 26 (4.5%) 49 (4.0%)
$20,000–$39,000 188 (10.5%) 58 (10.0%) 130 (10.7%)
$40,000–$59,000 262 (14.6%) 77 (13.3%) 185 (15.3%)
$60,000–$79,000 289 (16.1%) 97 (16.8%) 192 (15.8%)
$80,000–$99,000 243 (13.6%) 78 (13.5%) 165 (13.6%)
$100,000 734 (41.0%) 243 (42.0%) 491 (40.5%) 0.55*
Cardiac risk factors
Hypertension 1,108 (57.3%) 355 (57.0%) 753 (57.4%) 0.85
High cholesterol 1,498 (77.5%) 468 (75.1%) 1,030 (78.6%) 0.09
Diabetes mellitus 158 (8.2%) 52 (8.4%) 106 (8.1%) 0.85
Past smoker 803 (41.5%) 254 (40.8%) 549 (41.9%) 0.65
Current smoker 111 (5.7%) 37 (5.9%) 74 (5.6%) 0.80
Family history of CAD 513 (26.5%) 155 (24.9%) 358 (27.3%) 0.26
Body mass index, kg/m2 26.4 (23.9, 29.9) 26.3 (23.8, 29.7) 26.5 (23.9, 29.9) 0.23
Waist circumference, inches 36 (32.5, 39) 36 (32.3, 39) 36 (32.5, 39.3) 0.36
Medications
BP medications 622 (32.2%) 199 (32.1%) 423 (32.3%) 0.94
ACE inhibitors 205 (10.6%) 62 (10.0%) 143 (10.9%) 0.54
Beta-blockers 168 (8.7%) 64 (10.3%) 104 (8.0%) 0.08
Calcium-channel blockers 112 (5.8%) 29 (4.7%) 83 (6.4%) 0.15
Diuretics 225 (11.7%) 78 (12.6%) 147 (11.2%) 0.39
ARBs 104 (5.4%) 31 (5.0%) 73 (5.6%) 0.60
Others 51 (2.7%) 13 (2.1%) 38 (2.9%) 0.30
Lipid medications 501 (26.0%) 169 (27.3%) 332 (25.4%) 0.37
Statins 452 (23.5%) 152 (24.6%) 300 (22.9%) 0.43
Niacin 35 (1.8%) 11 (1.8%) 24 (1.8%) 0.93
Other lipid medications 56 (2.9%) 20 (3.2%) 36 (2.8%) 0.56
Diabetic medications 79 (4.1%) 28 (4.5%) 51 (3.9%) 0.53
Aspirin 246 (12.8%) 87 (14.1%) 159 (12.2%) 0.24
Clinical laboratory values, mg/dl
Total cholesterol 213 (187, 239) 213 (187, 238) 213 (187, 240) 0.44
HDL cholesterol 52 (42, 65) 53 (42, 65) 52 (42, 64) 0.58
LDL cholesterol 132 (110, 157) 130 (109, 155) 133 (111, 158) 0.15
Triglycerides 112 (79, 164) 113 (78, 166) 112 (79, 161) 0.99
Fasting glucose 93 (86, 101) 94 (86, 101) 93 (86, 101) 0.40
Systolic BP, mm Hg 131 (120, 143) 130 (119, 142) 131 (121, 144) 0.03
Diastolic BP, mm Hg 81 (75, 89) 81 (75, 89) 81 (76, 89) 0.41
Resting heart rate, beats/min 66 (59, 72) 66 (59, 72) 66 (60, 72) 0.73Values are mean  SD, n (%), or median (25th, 75th percentile). *Test for trend.
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blockers; BP  blood pressure; CAD  coronary artery disease; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
oW
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April 12, 2011:1622–32 Randomization to Coronary Calcium Scan Versus No ScanChange in Clinical Risk Factors, Medical Treatment, and Incurred CostsTable 2 Change in Clinical Risk Factors, Medical Treatment, and Incurred Costs
Parameters Study Group at Baseline No-Scan Group Scan Group p Value
CAD risk factors
Baseline SBP, mm Hg All subjects 130 (119, 142) 131 (121, 144) 0.03
Change in SBP, mm Hg All subjects 5 (16, 6) 7 (18, 3) 0.02
Baseline DBP, mm Hg All subjects 81 (75, 89) 81 (76, 89) 0.41
Change in DBP, mm Hg All subjects 4 (12, 4) 5 (12, 3) 0.50
Baseline cholesterol, mg/dl All subjects 213 (187, 238) 213 (187, 240) 0.44
Change in cholesterol, mg/dl All subjects 16 (44, 7) 21 (49, 6) 0.08
Baseline LDL, mg/dl All subjects 130 (109, 155) 133 (111, 158) 0.15
Change in LDL, mg/dl All subjects 11 (41, 10) 17 (44, 7) 0.04
Baseline HDL, mg/dl All subjects 53 (42, 65) 52 (42, 64) 0.58
Change in HDL, mg/dl All subjects 1 (7, 5) 1 (6, 5) 0.28
Baseline triglycerides, mg/dl All subjects 113 (78, 166) 112 (79, 161) 0.99
Change in triglycerides, mg/dl All subjects 9 (37, 14) 10 (42, 14) 0.40
Baseline glucose, mg/dl All subjects 94 (86, 101) 93 (86, 101) 0.40
Change in glucose, mg/dl All subjects 2 (8, 6) 0 (8, 7) 0.16
Baseline weight, lbs BMI25 kg/m2 186 (167, 210) 188 (166, 209) 0.66
Change in weight, lbs BMI25 kg/m2 1 (5, 8) 0 (6, 7) 0.07
Baseline WC, inches M40, W35 41 (38, 43) 41.3 (38, 43.5) 0.19
Change in WC, inches M40, W35 1 (2, 3) 0 (3, 2) 0.01
Quit smoking Smokers 16/36 (44%) 34/69 (49%) 0.64
Exercise 3 times/week Nonexercisers 95/266 (36%) 214/582 (37%) 0.77
Baseline FRS All subjects 6 (2, 12) 6 (2, 12) 0.45
Change in FRS* All subjects 0 (0, 2) 0 (1, 2) 0.003
New meds
Lipid meds No lipid meds 109/441 (25%) 284/963 (29%) 0.06
BP meds No BP meds 77/419 (18%) 214/877 (24%) 0.02
Diabetic meds No diabetic meds 15/595 (3%) 40/1260 (3%) 0.44
Aspirin No aspirin 39/525 (7%) 92/1130 (8%) 0.62
Meds adherence
Lipid meds On lipid meds 145/168 (86%) 281/325 (86%) 0.96
BP meds On BP meds 173/192 (90%) 388/414 (94%) 0.11
Diabetic meds On diabetic meds 26/28 (93%) 45/51 (88%) 0.71
Aspirin On aspirin 26/84 (31%) 43/158 (27%) 0.54
Performed procedures
Resting ECG All subjects 380 (61.0%) 767 (58.5%) 0.30
Stress nuclear All subjects 62 (10.0%) 169 (12.9%) 0.06
Stress echocardiography All subjects 102 (16.4%) 195 (14.9%) 0.39
Any stress test† All subjects 211 (33.9%) 454 (34.6%) 0.74
Cardiac CT All subjects 44 (7.1%) 101 (7.7%) 0.62
Carotid ultrasound All subjects 88 (14.1%) 167 (12.7%) 0.40
Cardiac catheterization All subjects 18 (2.9%) 43 (3.3%) 0.71
Coronary revascularization All subjects 11 (1.8%) 30 (2.3%) 0.46
Medical costs (in U.S. $)
Procedure costs All subjects 712 (523, 901) 904‡ (739, 1,056) 0.56
Medication costs All subjects 2,937 (2,620, 3,254) 3,149 (2,924, 3,374) 0.09
Lipid-lowering meds All subjects 721 (625, 817) 748 (682, 813) 0.06
BP meds All subjects 761 (659, 863) 892 (819, 966) 0.02
Diabetic meds All subjects 545 (415, 675) 533 (444, 623) 0.87
Aspirin All subjects 26 (20, 33) 27 (22, 31) 0.92
All costs All subjects 3,649 (3,263, 4,035) 4,053 (3,739, 4,367) 0.09
Values are median (25th, 75th percentile) or n (%). *Mean SD change in FRS was 0.7 5.1 versus 0.002 4.9 in the no-scan versus scan groups, respectively. †Stress nuclear, stress echocardiography,
r treadmill exercise electrocardiography (ECG). ‡Includes a $150 charge for coronary artery calcium scanning.
BMI  body mass index; CT  computed tomography; DBP  diastolic blood pressure; FRS  Framingham Risk Score; M  men; meds  medications; SBP  systolic blood pressure; W  women;
C  waist circumference; other abbreviations as in Table 1.
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Baseline SBP, mm Hg All subjects 128 (118, 140) 132 (122, 144.5) 138 (122, 149) 140 (125, 150) 0.001
Change in SBP, mm Hg All subjects 4 (16, 5) 9 (20, 2) 10.5 (21, 1) 9 (24, 2) 0.001
Baseline DBP, mm Hg All subjects 80 (74, 88) 82 (76, 90) 83 (78, 90) 82 (78, 90) 0.001
Change in DBP, mm Hg All subjects 4 (11, 5) 7 (14, 3) 5 (14, 2) 8 (12,1) 0.001
Baseline cholesterol, mg/dl All subjects 214 (190, 239) 211 (186.5, 242) 215 (188, 240) 210 (184, 237) 0.51
Change in cholesterol, mg/dl All subjects 15 (42, 9) 21 (50, 5) 30 (54,7) 39.5 (78, 0) 0.001
Baseline LDL, mg/dl All subjects 133 (111, 156) 133 (109, 160) 135 (109.5, 157) 135 (111, 158) 0.85
Change in LDL, mg/dl All subjects 12 (37, 10) 18.5 (50.5, 7) 25 (55,4) 29 (62, 3) 0.001
Baseline HDL, mg/dl All subjects 54 (44, 67) 51 (40, 62) 50 (41, 64) 49 (42, 59) 0.001
Change in HDL, mg/dl All subjects 1 (7, 5) 2 (6, 5) 0 (6, 5) 0 (5, 4) 0.46
Baseline triglycerides, mg/dl All subjects 106 (78, 154) 113 (79, 165.5) 120 (82, 180) 124 (86, 162) 0.003
Change in triglycerides, mg/dl All subjects 8 (35, 14) 8 (40, 19) 16 (53, 8) 25 (67, 4) 0.001
Baseline glucose, mg/dl All subjects 91 (85, 98) 94 (86, 103) 94 (87, 102) 97 (89, 108) 0.001
Change in glucose, mg/dl All subjects 1 (8, 6) 1 (8, 6) 1 (7, 9) 0 (10, 11) 0.34
Baseline weight, lbs BMI25 kg/m2 186 (165, 206) 188.5 (169, 208) 197 (169, 222) 186 (160, 214) 0.15
Change in weight, lbs BMI25 kg/m2 1 (5, 8) 0 (6, 6.5) 2 (9, 3.5) 3 (10, 3) 0.001
Baseline WC, inches M40, W35 41 (37.8, 43) 41.3 (39, 43) 42 (41, 43.5) 43 (39.6, 45.8) 0.002
Change in WC, inches M40, W35 0.5 (3.8, 2) 0.3 (2, 2) 1 (1, 2) 1 (3.3, 0.5) 0.56
Quit smoking Smokers 15/27 (56%) 13/24 (54%) 3/11 (27%) 3/7 (43%) 0.22
Exercise 3 times/week Nonexercisers 92/284 (32%) 75/188 (40%) 30/74 (41%) 17/36 (47%) 0.03
Baseline FRS All subjects 4 (2, 8) 8 (4, 16) 10 (4, 16) 16 (8, 20) 0.001
Change in FRS All subjects 0 (1, 2) 0 (2, 2) 0 (2, 2) 0 (2, 2) 0.003
New meds
Lipid meds No lipid meds 94/505 (19%) 96/274 (35%) 50/116 (43%) 44/68 (65%) 0.001
BP meds No BP meds 91/459 (20%) 63/249 (25%) 34/112 (30%) 26/57 (46%) 0.001
Diabetic meds No diabetic meds 12/617 (2%) 13/377 (3%) 5/165 (3%) 10/101 (10%) 0.001
Aspirin No aspirin 28/560 (5%) 31/349 (9%) 17/146 (12%) 16/75 (21%) 0.001
Meds adherence
Lipid meds On lipid meds 96/120 (80%) 105/117 (90%) 50/54 (93%) 30/34 (88%) 0.04
BP meds On BP meds 157/167 (94%) 135/144 (94%) 53/58 (91%) 43/45 (96%) 0.97
Diabetic meds On diabetic meds 14/14 (100%) 19/23 (83%) 6/6 (100%) 6/8 (75%) 0.18
Aspirin On aspirin 15/65 (23%) 12/42 (29%) 4/24 (17%) 12/27 (44%) 0.13
Performed procedures
Resting ECG All subjects 341 (54.0%) 236 (59.0%) 112 (65.5%) 78 (71.6%) 0.001
Stress nuclear All subjects 38 (6.0%) 59 (14.8%) 34 (19.9%) 38 (34.9%) 0.001
Stress echocardiography All subjects 70 (11.1%) 57 (14.3%) 38 (22.2%) 30 (27.5%) 0.001
Any stress test All subjects 155 (24.6%) 144 (36.0%) 85 (49.7%) 70 (64.2%) 0.001
Cardiac CT All subjects 44 (7.0%) 28 (7.0%) 14 (8.2%) 15 (13.8%) 0.04
Carotid ultrasonography All subjects 76 (12.0%) 43 (10.8%) 30 (17.5%) 18 (16.5%) 0.07
Catheterization All subjects 7 (1.1%) 10 (2.5%) 10 (5.9%) 16 (14.7%) 0.001
Revascularization All subjects 1 (0.2%) 4 (1.0%) 9 (5.3%) 16 (14.7%) 0.001
Medical costs (in U.S. $)
Procedure costs 899 (733, 1,066) 447 (352,543) 705 (450,960) 1,130 (778, 1,483) 3,774 (2,302, 5,247) 0.001
Meds costs 3,131 (2,904, 3,357) 2,176 (1,922, 2,429) 3,689 (3,265, 4,113) 3,769 (3,058, 4,480) 5,534 (4,457, 6,613) 0.001
Lipid-lowering meds 825 (755, 895) 581 (491,671) 1,025 (886,1,163) 991 (790, 1,191) 1,232 (979, 1,485) 0.001
BP meds 896 (822, 970) 722 (623,820) 1,072 (924,1,219) 866 (671, 1,061) 1,318 (1,045, 1,590) 0.001
Diabetic meds 529 (439, 619) 367 (259,476) 617 (436,798) 569 (325, 813) 1,077 (652, 1,502) 0.001
Aspirin 27 (22, 31) 16 (11, 21) 31 (22, 41) 31 (18, 45) 66 (42, 89) 0.001
All costs 4,030 (3,714, 4,346) 2,623 (2,343, 2,903) 4,394 (3,856, 4,931) 4,900 (3,992, 5,807) 9,309 (7,200, 11,418) 0.001Values are median (25th, 75th percentile) or n (%).
CAC  coronary artery calcium; other abbreviations as in Tables 1 and 2.
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Parameters Study Group at Baseline No-Scan Group CAC Score 0 p Value
CAD risk factors
Baseline SBP, mm Hg All subjects 130 (119, 142) 128 (118, 140) 0.14
Change in SBP, mm Hg All subjects 5 (16, 6) 4 (16, 5) 0.73
Baseline DBP, mm Hg All subjects 81 (75, 89) 80 (74, 88) 0.14
Change in DBP, mm Hg All subjects 4 (12, 4) 4 (11, 5) 0.09
Baseline cholesterol, mg/dl All subjects 213 (187, 238) 214 (190, 239) 0.31
Change in cholesterol, mg/dl All subjects 16 (44, 7) 15 (42, 9) 0.45
Baseline LDL, mg/dl All subjects 130 (109, 155) 133 (111, 156) 0.29
Change in LDL, mg/dl All subjects 11 (41, 10) 12 (37, 10) 0.87
Baseline HDL, mg/dl All subjects 53 (42, 65) 54 (44, 67) 0.14
Change in HDL, mg/dl All subjects 1 (7, 5) 1 (7, 5) 0.42
Baseline triglycerides, mg/dl All subjects 113 (78, 166) 106 (78, 154) 0.17
Change in triglycerides, mg/dl All subjects 9 (37, 14) 8 (35, 14) 0.81
Baseline glucose, mg/dl All subjects 94 (86, 101) 91 (85, 98) 0.001
Change in glucose, mg/dl All subjects 2 (8, 6) 1 (8, 6) 0.27
Baseline weight, lbs BMI25 kg/m2 186 (167, 210) 186 (165, 206) 0.60
Change in weight, lbs BMI25 kg/m2 1 (5, 8) 1 (5, 8) 0.87
Baseline WC, inches M40, W35 41 (38, 43) 41 (37.8, 43) 0.91
Change in WC, inches M40, W35 1 (2, 3) 0.5 (3.8, 2) 0.003
Quit smoking Smokers 16/36 (44%) 15/27 (56%) 0.38
Exercise 3 times/week Nonexercisers 95/266 (36%) 92/284 (32%) 0.41
Baseline FRS All subjects 6 (2, 12) 4 (2, 8) 0.001
Change in FRS All subjects 0 (0, 2) 0 (1, 2) 0.22
New meds
Lipid meds No lipid meds 109/441 (25%) 94/505 (19%) 0.02
BP meds No BP meds 77/419 (18%) 91/459 (20%) 0.59
Diabetic meds No diabetes meds 15/595 (3%) 12/617 (2%) 0.50
Aspirin No aspirin 39/525 (7%) 28/560 (5%) 0.10
Meds adherence
Lipid meds On lipid meds 145/168 (86%) 96/120 (80%) 0.15
BP meds On BP meds 173/192 (90%) 157/167 (94%) 0.18
Diabetic meds On diabetes meds 26/28 (93%) 14/14 (100%) 0.55
Aspirin On aspirin 26/84 (31%) 15/65 (23%) 0.29
Performed procedures
Resting ECG All subjects 380 (61.0%) 341 (54.0%) 0.01
Stress nuclear All subjects 62 (10.0%) 38 (6.0%) 0.01
Stress echocardiography All subjects 102 (16.4%) 70 (11.1%) 0.007
Any stress test All subjects 211 (33.9%) 155 (24.6%) 0.001
Cardiac CT All subjects 44 (7.1%) 44 (7.0%) 0.95
Carotid ultrasonography All subjects 88 (14.1%) 76 (12.0%) 0.28
Cardiac catheterization All subjects 18 (2.9%) 7 (1.1%) 0.02
Coronary revascularization All subjects 11 (1.8%) 1 (0.2%) 0.003
Medical costs (in U.S. $)
Procedure costs All subjects 712 (523, 901) 447 (351, 543) 0.001
Meds costs All subjects 2,937 (2,620, 3,254) 2,176 (1,922, 2,429) 0.005
Lipid-lowering meds All subjects 721 (625, 817) 581 (491, 671) 0.02
BP meds All subjects 761 (659, 863) 722 (623, 820) 0.78
Diabetic meds All subjects 545 (415, 675) 367 (259, 476) 0.02
Aspirin All subjects 26 (20, 33) 16 (11, 21) 0.02
All costs All subjects 3,649 (3,263, 4,035) 2,623 (2,343, 2,903) 0.001Values are median (25th, 75th percentile) or n (%).
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progression included age (odds ratio [OR]: 1.20 per 5 years;
95% confidence interval [CI]: 1.1 to 1.3; p  0.001), male sex
(OR: 2.02; 95% CI: 1.6 to 2.6; p  0.001), family history of
AD (OR: 1.47; 95%CI: 1.1 to 1.9; p 0.006), hypertension
OR: 1.38; 95%CI: 1.1 to 1.8; p 0.01), hyperlipidemia (OR:
.44; 95% CI: 1.05 to 2.0; p  0.03), and history of diabetes
(OR: 1.69; 95% CI: 1.1 to 2.7; p  0.03). In the final
treatment plus baseline model, lipid-lowering medication use
by year 4 was the strongest predictor of CAC score progression
(OR: 1.51; 95% CI: 1.2 to 2.0; p  0.002).
Discussion
To assess the impact of CAC scanning on CAD risk, we
randomly assigned asymptomatic subjects to groups under-
going CAC scan versus no CAC scan and compared the
groups for 4-year changes in CAD risk. In total, 7 modifi-
able CAD risk factors were assessed: blood pressure, lipid
profiles, serum glucose, weight, waist circumference, exer-
cise, and smoking. Subjects who underwent CAC scanning
experienced a favorable improvement in risk, including
greater reduction in mean systolic blood pressure and serum
LDL cholesterol level, and reduced waist circumference for
those with increased abdominal girth at baseline. The
overweight subjects within the scan group also showed a
tendency toward more weight loss compared with their
no-scan counterparts. The 2 groups did not differ in exercise
activity, smoking behavior, or glucose measurements at 4
years, but the frequencies of smokers and diabetic patients in
our study were both low. Four-year progression of CAD
risk, as summarized by FRS, rose in the no-scan group but
was static in the scan group, due to the favorable improve-
ments in systolic blood pressure and lipid status. Impor-
tantly, risk factor profiles improved in both the scan and
no-scan groups after recruitment into our trial, but the
magnitude of improvement was greater in the scan group.
Overall rates of downstream medical testing and proce-
dures did not differ among the scan and no-scan groups,
resulting in comparable medical procedure costs during
follow-up. Estimated medication costs were mildly higher
in the scan group.
There was no substantive difference in the rates of
myocardial infarction or fatal events between the 2 random-
ized groups; however, the rates of events were low and
statistical power was insufficient to adequately assess this
issue. Practical study of how CAC scanning might affect
clinical events may require studying patients, rather than
healthy volunteers, who may be pre-selected to be at higher
risk of clinical events compared with our subjects (11).
Change in CAD risk factors, downstream tests, and
incurred costs according to baseline CAC score. Within
the scan group, there was a direct proportional relationship
between the magnitude of baseline CAC and the degree of
reduction of systolic and diastolic blood pressure, serum
cholesterol, LDL, and triglyceride levels. In addition, areduction in waist size occurred among subjects with in-
creased abdominal girth and high CAC scores, and modest
weight loss occurred among overweight subjects with CAC
score elevation. Factors not varying according to CAC score
included HDL cholesterol, glucose measurements, and
smoking cessation. The composite FRS at 4 years increased
compared with the baseline FRS among the scan subjects
with a zero CAC score and decreased among subjects with
elevated CAC scores.
There was a strong proportional relationship between
baseline CAC score and the frequency of initiating cardiac
medications. Downstream medical testing also increased in
proportion to baseline CAC score. Both procedural and
medical costs were substantially higher in the subjects with
a CAC score 400 compared with subjects having a CAC
score of 100 to 399. Noninvasive stress testing predomi-
nated among downstream tests. Overall, approximately
two-thirds of subjects with CAC scores 400 underwent
some form of cardiac stress testing, but the frequency of
4-year rates of cardiac catheterization and coronary revas-
cularization were substantially lower. Because of the design
of our trial, we were uniquely able to assess how knowledge
of a normal CAC scan influenced the forward trajectory of
medical treatment and costs compared with usual medical
care. Overall, there was a 25% greater reduction in medi-
cation costs in the normal CAC scan subjects compared
with the no-scan group, and a 37% reduction in procedure
costs. Since the normal scan subjects constituted 50% of
our scan subjects, whereas the subjects with CAC scores
400 constituted only 8% of our scan subjects, these
directionally opposite effects were sufficient to result in the
comparable incurred costs within our scan and no-scan
groups.
Assessment of CAC scores at 4 years. There was no
difference in mean CAC scores or the distribution of CAC
scores in the no-scan versus scan group at 4 years. Within
the scan group, we found that both baseline CAD risk
factors and the use of lipid-lowering medication were
predictors of CAC score progression. These findings paral-
lel that of the MESA study (12). While some early studies
reported that the use of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins)
was associated with a reduced rate of CAC progression
during serial scanning (13,14), subsequent studies have
reported either no difference in CAC progression (15–17)
or even increased rate of CAC progression among subjects
using such medication (12,18). Of note in this regard is
experimental work suggesting that statins may have the
ability to promote calcification of coronary plaques (19).
While further study is indicated, the apparent multifactorial
causation for plaque progression limits the use of CAC
score progression as a therapeutic index.
Comparison to prior studies. Only 1 prior randomized
trial, conducted by O’Malley et al. (20), has assessed the
impact of CAC scanning on subjects’ risk profiles and
health behavior, and there are no prior trials concerning the
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the trial conducted by O’Malley et al. (20), subjects under-
went CAC scanning, but the results were then withheld in
one-half of subjects. In contrast to our study, these inves-
tigators found no impact of CAC scanning on subjects’
clinical profile. However, their study was primarily limited
to young military personnel with a mean age of only 42
years, and 85% had normal CAC scans, thus limiting the
comparability of their findings to our own.
Study limitations. Our subjects were highly educated,
fairly affluent, and sufficiently motivated to volunteer for our
research study, and were thus more likely than a general
population to adhere to risk factor modification therapies.
Indeed, the 90% 4-year continuation rate for using lipid-
lowering and antihypertensive medication in our study is
atypically high compared with studies involving patient
populations (21). In addition, our study and the prior study
by O’Malley et al. (20) are similarly limited in that they
involved the offering of free CAC scans to volunteer
subjects. This incentive offering may not be reflective of the
care path that patients may encounter when confronted with
out-of-pocket CAC scan costs from the onset or when the
scan is ordered by a physician. For these reasons, caution
should be applied in generalizing our findings to popula-
tions at large.
Because of the limited assessment of health behaviors in
our study, we could not determine the extent to which CAC
scanning drove reduced CAD risk profiles due to improve-
ment in subjects’ health behaviors as opposed to more
intensive use and adherence to medications. An objective
measure of dietary habits was lacking in our study, and our
assessment of exercise activity relied on a crude self-report
measurement rather than on objective measurements, such
as can be garnered by pedometer use. Further, the nature of
our study design, involving only a 1-time counseling session,
might not be ideal for inducing behavioral lifestyle
changes that are more difficult to accomplish compared with
taking medications. Thus, future study might compare if
and what intensity of behavioral interventions improves the
ability of CAC scanning to improve patients’ lifestyle health
behaviors.
The impact of CAC scanning on diabetes and smoking
could not be adequately assessed in our trial, owing to our
small number of subjects with these risk factors. In addition,
we cannot exclude that the nature of our study design led to
psychological effects whereby subjects who were randomized
to the scan group—and thus received a free CAC scan at
both onset and at 4 years—felt more motivated to partici-
pate in our trial, and those who were randomized to the
no-scan group felt discouraged that CAC scanning would
be deferred for 4 years. Potentially, this dynamic might
explain the greater loss to follow-up that was noted among
the no-scan subjects.
Another important methodological limitation was that
due to anonymity restrictions imposed by our institutional
review board, we could not provide CAC scan resultsdirectly to our subjects’ physicians. As a result, their involve-
ment only occurred indirectly. However, this limitation may
have served to actually minimize the potential impact of
CAC scanning upon risk factor management in our study.
Conversely, our study design may have limited our ability to
assess the financial impact of CAC scanning in clinical
practice, as the actual course of action following calcium
scanning may be potentially different when testing is or-
dered by a physician rather than being initiated by subjects
seeking to assess their cardiovascular risk. For example, after
their ordering of a CAC scan, physicians may feel more
compelled than volunteer subjects to do follow-up stress
testing in patients with intermediate to high CAC scores for
fear of medicolegal consequences for a missed work-up for
myocardial ischemia. Accordingly, more prospective study is
required to assess the financial impact of CAC scanning
upon downstream testing and medical costs in actual clinical
practice.
Clinical implications. The results of our trial are consis-
tent with the hypothesis that CAC scanning can improve
cardiac management without incurring significant increase
in downstream medical costs. Further work should similarly
assess patients who are suitable candidates for CAC scan-
ning based on clinical consensus and current guidelines
(22–24). Notably, the finding that our study did not lead to
increased downstream testing is potentially clinically signif-
icant, revealing that physicians may be applying a “gate-
keeper” function to CAC scanning with respect to ascer-
taining the need for subsequent more expensive noninvasive
testing. This potential use may be based on the repeated
observation of a threshold relationship between the magni-
tude of CAC abnormality and the likelihood of observing
inducible myocardial ischemia (8,25–28). The results of our
study indicate a need for future large-scale clinical trials to
determine whether our findings are applicable to different
patient populations and to determine whether the salutatory
effect of CAC scanning on CAD risk profiles translates to
reductions in adverse clinical events. Such trials should
evaluate outcomes following CAC scanning not only ac-
cording to the efficacy and intensity of medications used to
control CAD risk factors, but also according to the quality
and intensity of behavioral interventions instituted after
CAC scanning.
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